Automatic identification of high impact articles in PubMed to support clinical decision making

被引:9
作者
Bian, Jiantao [1 ]
Morid, Mohammad Amin [2 ]
Jonnalagadda, Siddhartha [3 ]
Luo, Gang [4 ]
Del Fiol, Guilherme [1 ]
机构
[1] Univ Utah, Dept Biomed Informat, 421 Wakara Way, Salt Lake City, UT 84108 USA
[2] Univ Utah, David Eccles Sch Business, Dept Operat & Informat Syst, Salt Lake City, UT 84108 USA
[3] Microsoft Corp, One Microsoft Way, Redmond, WA 98052 USA
[4] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA
关键词
QUESTIONS; RETRIEVAL; QUALITY; MANAGEMENT; GUIDELINE; QUERIES; NEEDS;
D O I
10.1016/j.jbi.2017.07.015
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Objectives: The practice of evidence-based medicine involves integrating the latest best available evidence into patient care decisions. Yet, critical barriers exist for clinicians' retrieval of evidence that is relevant for a particular patient from primary sources such as randomized controlled trials and meta analyses. To help address those barriers, we investigated machine learning algorithms that find clinical studies with high clinical impact from PubMed (R). Methods: Our machine learning algorithms use a variety of features including bibliometric features (e.g., citation count), social media attention, journal impact factors, and citation metadata. The algorithms were developed and evaluated with a gold standard composed of 502 high impact clinical studies that are referenced in 11 clinical evidence-based guidelines on the treatment of various diseases. We tested the following hypotheses: (1) our high impact classifier outperforms a state-of-the-art classifier based on citation metadata and citation terms, and PubMed's (R) relevance sort algorithm; and (2) the performance of our high impact classifier does not decrease significantly after removing proprietary features such as citation count. Results: The mean top 20 precision of our high impact classifier was 34% versus 11% for the state-of-the-art classifier and 4% for PubMed's (R) relevance sort (p = 0.009); and the performance of our high impact classifier did not decrease significantly after removing proprietary features (mean top 20 precision = 34% vs. 36%; p = 0.085). Conclusion: The high impact classifier, using features such as bibliometrics, social media attention and MEDLINE (R) metadata, outperformed previous approaches and is a promising alternative to identifying high impact studies for clinical decision support. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 62 条
  • [51] Evidence based medicine: What it is and what it isn't (reprinted from BMJ, vol 312, pg 71-72, 1996)
    Sackett, David L.
    Rosenberg, William M. C.
    Gray, J. A. Muir
    Haynes, R. Brian
    Richardson, W. Scott
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2007, (455) : 3 - 5
  • [52] Comparative effectiveness research: Relevance and applications to pharmacy
    Schumock, Glen T.
    Pickard, A. Simon
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (14) : 1278 - 1286
  • [53] A hybrid intelligent system for medical data classification
    Seera, Manjeevan
    Lim, Chee Peng
    [J]. EXPERT SYSTEMS WITH APPLICATIONS, 2014, 41 (05) : 2239 - 2249
  • [54] 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
    Singh, Jasvinder A.
    Furst, Daniel E.
    Bharat, Aseem
    Curtis, Jeffrey R.
    Kavanaugh, Arthur F.
    Kremer, Joel M.
    Moreland, Larry W.
    O'Dell, James
    Winthrop, Kevin L.
    Beukelman, Timothy
    Bridges, S. Louis, Jr.
    Chatham, W. Winn
    Paulus, Harold E.
    Suarez-Almazor, Maria
    Bombardier, Claire
    Dougados, Maxime
    Khanna, Dinesh
    King, Charles M.
    Leong, Amye L.
    Matteson, Eric L.
    Schousboe, John T.
    Moynihan, Eileen
    Kolba, Karen S.
    Jain, Archana
    Volkmann, Elizabeth R.
    Agrawal, Harsh
    Bae, Sangmee
    Mudano, Amy S.
    Patkar, Nivedita M.
    Saag, Kenneth G.
    [J]. ARTHRITIS CARE & RESEARCH, 2012, 64 (05) : 625 - 639
  • [55] Pharmaceutical company funding and its consequences: A qualitative systematic review
    Sismondo, Sergio
    [J]. CONTEMPORARY CLINICAL TRIALS, 2008, 29 (02) : 109 - 113
  • [56] Soni J., 2011, INT J COMPUT APPL, V17, P43, DOI [10.5120/2237-2860, DOI 10.5120/2237-2860]
  • [57] Tsymbal A., 2004, PROBLEM CONCEPT DRIF
  • [58] Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Koehne, Claus-Henning
    Hitre, Erika
    Zaluski, Jerzy
    Chien, Chung-Rong Chang
    Makhson, Anatoly
    D'Haens, Geert
    Pinter, Tamas
    Lim, Robert
    Bodoky, Gyoergy
    Roh, Jae Kyung
    Folprecht, Gunnar
    Ruff, Paul
    Stroh, Christopher
    Tejpar, Sabine
    Schlichting, Michael
    Nippgen, Johannes
    Rougier, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) : 1408 - 1417
  • [59] Widmer G, 1996, MACH LEARN, V23, P69, DOI 10.1023/A:1018046501280
  • [60] An overview of the design and methods for retrieving high-quality studies for clinical care
    Wilczynski N.L.
    Morgan D.
    Haynes R.B.
    [J]. BMC Medical Informatics and Decision Making, 5 (1)